Prognostic Impact of PD-1 Polymorphisms in Non-small Cell Lung Cancer Receiving Dendritic Cell Vaccination
DC vaccination with WT1 and/or MUC1 peptides combined with salvage chemotherapy appears to be a promising treatment strategy for patients with advanced or relapsed NSCLC. The PD-1 rs36084323 SNP, along with PNI, was identified as an independent prognostic factor, suggesting its potential utility as a biomarker for selecting appropriate candidates for this treatment approach.
Authors
- Masahiro Ogasawara (ORCID: https://orcid.org/0000-0002-7919-7146)
- MAMIKO MIYASHITA
- Shuichi Ota (ORCID: https://orcid.org/0000-0002-3631-244X)
- Yuka Yamagishi
Institutions
- Sapporo Hokuyu Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.21873/anticanres.17780
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00